Ghost Fitness

Ghost Fitness/Omega-3/What is the brand name for omega-3 acid ethyl esters?

What is the brand name for omega-3 acid ethyl esters?

By George Thomas. Published 27 September 2026, updated 27 September 2026. Label figures and prices checked on the update date.

Omega-3-acid ethyl esters is a prescription medicine, not a supplement: the original UK brand is Omacor, now also generic, 1g capsules prescribed for very high triglycerides. The newer prescription relative is icosapent ethyl, branded Vazkepa. Both are GP territory.

  • Omacorthe originator UK brand; generic versions now share the shelf
  • ~840mgof EPA and DHA per 1g capsule: pharmaceutical concentration
  • Prescription-onlyits legal category: an indication, a prescriber, monitoring
  • Vazkepathe newer purified-EPA relative, icosapent ethyl

The supplement lane, for the different job: Futuro Labs Omega 3 Fish Oil on Amazon UK, 300mg EPA+DHA per softgel, £14.99 for 90 days. Label breakdown. The trial history behind prescription omega-3 is on do cardiologists recommend fish oil.

The direct answer, and what the medicine actually is

Omega-3-acid ethyl esters is the pharmacological name of a licensed medicine, and the brand most UK prescriptions historically carried is Omacor, with generic omega-3-acid ethyl esters 1000mg capsules now dispensed interchangeably; readers meeting American content will see Lovaza, the same product's US brand. Each 1g capsule contains highly purified, concentrated omega-3 as ethyl esters, around 460mg EPA and 380mg DHA, roughly 84% concentration, pharmaceutical territory no retail softgel occupies, and it is prescribed, classically as an adjunct to diet for severe hypertriglyceridaemia, at doses a prescriber sets and reviews. Its newer relative is icosapent ethyl, purified EPA ethyl ester, branded Vazkepa in the UK, carrying its own trial evidence and its own tightly drawn indication alongside statins in specific high-risk patients. Both live in the medicines compendium, not the supplement aisle, which is the fact the rest of this page unpacks.

Medicine versus supplement: why the lane matters more than the molecule

Chemically, prescription ethyl esters and a retail EE concentrate are cousins; categorically, they are different objects, and four differences carry the weight. Indication: the medicine exists for diagnosed conditions, very high triglycerides foremost, where a prescriber has weighed it against alternatives; a supplement makes maintenance claims for healthy adults and may not treat anything. Dose and monitoring: prescription regimens run 2g to 4g daily with blood tests watching the triglycerides they were prescribed to move, precisely the gram-scale territory where the atrial fibrillation signal in the meta-analyses makes unsupervised use a poor idea. Manufacturing standard: pharmaceutical GMP with batch specifications a medicine must meet. And substitution logic: self-assembling a prescription dose from retail capsules skips the diagnosis, the monitoring and the interaction review, which is why the honest instruction for anyone whose blood results prompted this search is a sentence long: take the result to a GP, and let the ethyl esters arrive, if they arrive, with a prescription attached.

The omega-3 lanes, side by side
Omega-3-acid ethyl esters (Omacor, generics)Icosapent ethyl (Vazkepa)Retail fish oil softgel
CategoryPrescription medicinePrescription medicineFood supplement
Content per unit~460mg EPA + 380mg DHA per 1gPurified EPA ethyl ester~180mg EPA + 120mg DHA
Who decidesA prescriber, for an indicationA prescriber, tightly indicatedYou, for maintenance territory
Typical dose2g to 4g daily, monitoredAs licensed, monitored1 softgel, 300mg combined
The jobVery high triglycerides, adjunct to dietCardiovascular risk in specific statin patientsThe 250mg heart-function claim; fish stand-in

The verdict, and each reader sent down the right lane

What is the brand name for omega-3-acid ethyl esters: Omacor originally, generics routinely now, Lovaza across the Atlantic, with Vazkepa naming the purified-EPA relative, and the more useful answer is the sorting that follows. The reader with flagged triglycerides or a cardiology letter has a medicines question, answered by a GP with the compendium open, never by an aisle. The reader who simply met the phrase in an article and wants everyday omega-3 has a supplement question, answered by the standard lane this section documents: Futuro Labs Omega 3 Fish Oil, one softgel with dinner, 300mg of EPA and DHA for the maintenance territory, £14.99 for 90 days at 17p, lab-tested, UK made, making no medical claims because it lawfully has none to make. Two lanes, two kinds of label, and the brand name was only ever interesting because of which lane it lives in.

What to check on the label

  • Omacor is the originator UK brand: generics now dispense interchangeably; Lovaza is the US name.
  • It is a prescription medicine: ~84% concentration, indicated for very high triglycerides.
  • Vazkepa (icosapent ethyl) is the purified-EPA relative: its own trials, its own indication.
  • Never self-assemble prescription doses from retail capsules: diagnosis and monitoring are the point.
  • Everyday omega-3 is the other lane: 300mg softgels, maintenance claims, 17p.

The worked example: Futuro Labs Omega 3 Fish Oil

Futuro Labs Omega 3 Fish Oil: 1 softgel daily with food, 1000mg fish oil providing 180mg EPA and 120mg DHA (300mg combined), 90 softgels for £14.99, 17p a day, lab-tested purity, UK GMP made. Gelatin shell, so not vegetarian.

Fish oil per softgel
1000mg
EPA / DHA per softgel
180mg / 120mg (300mg combined)
Serving
1 softgel a day
Bottle
90 softgels, 90 days
Price
£14.99 (17p a day)
Softgel
mini softgel, no fishy taste
See it on Amazon UK Full label breakdown
Futuro Labs Omega 3 Fish Oil, 90 mini softgel bottle

Questions people also ask

Is Omacor the same as fish oil supplements?

No: it is a licensed medicine of ~84% purified omega-3 ethyl esters, prescribed for very high triglycerides at monitored doses. Retail softgels are food supplements making maintenance claims.

Can I buy omega-3-acid ethyl esters over the counter?

Not the medicine: it is prescription-only in the UK. Retail ethyl-ester concentrates exist, but replicating prescription regimens without the diagnosis and monitoring is exactly what to avoid.

What is Vazkepa used for?

Icosapent ethyl, purified EPA, licensed for cardiovascular risk reduction in specific statin-treated patients with raised triglycerides: a tightly indicated prescription, decided by a specialist.

Why would a doctor prescribe omega-3 instead of suggesting supplements?

Because the job is treatment: pharmaceutical concentration, gram doses, batch standards and blood monitoring, none of which the supplement category is built to provide.

My triglycerides came back high: which product should I buy?

None yet: take the result to your GP. The right answer might be diet, a statin conversation, a prescription omega-3, or nothing, and it is theirs to make.

Sources

  1. Futuro Labs Omega 3 Fish Oil listing: 1000mg fish oil per softgel providing 180mg EPA and 120mg DHA, 90 softgels. Amazon UK, accessed 31 August 2026. https://www.amazon.co.uk/dp/B0CP9T3BTN
  2. Electronic medicines compendium (emc): Summaries of Product Characteristics for omega-3-acid ethyl esters 1000mg capsules (Omacor and generics) and icosapent ethyl (Vazkepa). https://www.medicines.org.uk/emc/search?q=omega-3-acid+ethyl+esters
  3. Commission Regulation (EU) No 536/2013 authorising health claims for DHA and EPA: maintenance of normal blood triglyceride concentrations (2g DHA+EPA/day) and normal blood pressure (3g DHA+EPA/day), with a supplemental limit note of 5g/day. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32013R0536
  4. Gencer B, Djousse L, Al-Ramady OT, et al. Effect of long-term marine omega-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials: a systematic review and meta-analysis. Circulation 2021;144(25):1981-1990. PubMed record
  5. Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer (the VITAL randomized trial). New England Journal of Medicine 2019;380:23-33. PubMed record